Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors

Status: Recruiting
Phase: Phase 1
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
NCT ID: NCT01609556 (View complete trial on
DFCI Protocol ID: 12-312


The purpose of this study is to test IMGN853 in patients with FOLR-1 positive tumors.


Conducting Institutions:
Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women's Hospital

Overall PI:
Michael Birrer, MD, PhD, Massachusetts General Hospital

Site-responsible Investigators:
Ursula Matulonis, MD, Dana-Farber Cancer Institute

Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100
Dana-Farber Cancer Institute: Christin Whalen, 617-582-7738,

Eligibility Criteria

Inclusion Criteria: 1. Diagnosis, allowable prior therapy, and disease measurability requirements: A. Dose Escalation Phase: All patients must have a pathologically documented, definitively diagnosed, advanced solid tumor that is refractory to standard treatment, for which no standard treatment is available. Enrollment without prior documentation of tumor FOLR1 expression will be limited to the following histologic subtypes, which have a high incidence of FOLR1 positivity: 1. Serous or endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer 2. Serous endometrial cancer 3. Adenocarcinoma or BAL NSCLC 4. Clear cell renal carcinoma 5. Additional tumor types may be eligible, but require documented expression of FOLR1 (≥1 focal) by IHC (see IMGN853 laboratory manual for IHC screening procedures) 6. There is no upper limit on the number of prior cytotoxic or targeted therapies the patient may have received. Patients may have received prior treatment with investigational compounds targeting FOLR1. 7. Patients must have measurable or non-measurable disease. B. Dose Expansion Cohort 1: Patients must have EOC, which is refractory or resistant to primary, platinum-based chemotherapy: 1. Patients must have histologically-confirmed EOC, primary peritoneal cancer or fallopian tube cancer 2. Patients must have confirmation of ≥2 heterogeneous FOLR1 positivity by IHC. 3. Patients must have received prior platinum-based therapy for management of primary disease but must not have received more than 2 prior systemic cytotoxic chemotherapy regimens. If the patient has received a second cytotoxic regimen, this regimen should not have included a platinum component. 4. Patients may have received additional therapy with targeted agents (no upper limit), except those directed at FOLR1. 5. Patients must have at least one lesion that meets the definition of measurable according to RECIST 1.1 (Appendix D). C. Dose Expansion Cohort 2: Patients must have relapsed or refractory EOC, which is amenable to biopsy 1. Patients must have histologically-confirmed EOC, primary peritoneal cancer or fallopian tube cancer who have progressed during or following completion of standard therapy 2. Patients must be willing to undergo tumor biopsy prior to the first dose of IMGN853 and 7±3 days after the first IMGN853 dose. 3. Patients must have confirmation of ≥2 heterogeneous FOLR1 positivity by IHC. 4. There is no upper limit on the number of prior treatment regimens (cytotoxic and/or targeted therapies) the patient may have received; however, prior treatment with FOLR1-targeted agents is not allowed. 5. Patients must have measurable or non-measurable disease that can be safely biopsied. D. Dose Expansion Cohort 3: Patients must have a histologically or cytologically-confirmed diagnosis of NSCLC adenocarcinoma, and must be refractory to or intolerant of standard therapy 1. Patients must be willing to undergo 18FLT-PET imaging and/or tumor biopsy prior to the first dose of IMGN853 and 7±3 days after the first IMGN853 dose. 2. Patients must have confirmation of ≥ 2 heterogeneousFOLR1-positivity by IHC 3. There is no upper limit on the number or prior treatment regimens the patient may have received (cytotoxic and/or targeted therapies); however, prior treatment with FOLR1-targeted agents is not allowed. 4. Patients must have measurable or non-measurable disease. 2. Patients with accessible malignant effusions, such as ascites, must sign an additional informed consent to have serial biopsy to measure soluble FOLR1 (pre-dose and 7±3 days after the first IMGN853 dose). 3. Patients must be willing to provide an archival tumor tissue block or slides for biomarker analysis 4. > 18 years old at the time of informed consent; 5. ECOG Performance Status 0 or 1 6. Time from Prior Therapy: 1. Systemic Anti-Neoplastic Therapy: five half-lives or four weeks, whichever is shorter (6 weeks for prior nitrosoureas or mitomycin C) 2. Radiotherapy: wide-field radiotherapy (e.g. > 30% of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study drug 7. Patients must have recovered or stabilized from all therapy-related toxicities. 8. Major surgery (not including placement of vascular access device or tumor biopsies) must be completed four weeks prior to Day 1. Patients must have recovered or stabilized from the side effects prior to study treatment. 9. Patients must have adequate hematologic, liver and kidney function as defined by the following parameters: 1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L 2. Platelet count ≥ 1.0 x 109/L (must not have been transfused within previous 10 days) 3. Hemoglobin ≥ 9.0 g/dL, 4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or 24-hour creatinine clearance of ≥ 60 mL/minute, 5. AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN (AST, ALT < 5 x ULN if liver metastases), and 6. Serum bilirubin ≤ 1.5 x UNL 10. Patients with CNS disease involvement are eligible if they have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to study day 1 and they meet all of the following criteria: (1) residual neurological symptoms ≤ grade 1 (2) No dexamethasone requirement, and (3) Follow-up MRI shows no progression of treated lesions and no new lesions appearing. 11. Patients must be willing and able to sign the informed consent form, and to adhere to the study visit schedule and other protocol requirements 12. Women of child bearing potential (WCBP), defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months) must agree to use effective contraceptive methods; examples include oral, parenteral, or implantable hormonal contraceptive, intra-uterine device, barrier contraceptive with spermicide, partner's latex condom or vasectomy) while on study treatment and for at least twelve weeks after the last dose of study drug. 13. WCBP must have a negative pregnancy test prior to the first dose of study treatment 14. Male patients must agree to use a latex condom even if he has had a successful vasectomy and continue to follow these requirements for at least twelve weeks following the last dose of study drug. Exclusion Criteria: 1. Grade >1 neuropathy 2. Any active or chronic corneal disorder. 3. Serious concurrent illness, including, but not limited to the following: 1. Clinically relevant active infection including known active hepatitis B or C, Human Immunodeficiency Virus (HIV) infection, varicella-zoster virus (shingles) or cytomegalovirus infection or any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of study enrollment 2. Significant cardiac disease such as recent myocardial infarction (≤ 6 months prior to Day 1), unstable angina pectoris, uncontrolled congestive heart failure (New York Heart Association > class II), uncontrolled hypertension (≥ CTCAE v4.03 Grade 3), uncontrolled cardiac arrhythmias, severe aortic stenosis, or ≥ grade 3 cardiac toxicity following prior chemotherapy 3. History of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last 6 months, or alcoholic liver disease. 4. Any other concomitant anti-cancer treatment such as immunotherapy, biotherapy, radiotherapy, chemotherapy, investigative therapy, or high-dose steroids; however, low-dose steroids and Luteinizing Hormone Releasing Hormone (LHRH) at doses that have been stable for ≥ 14 days are permitted for patients with prostate cancer 5. Known hypersensitivity to previous monoclonal antibody therapy or maytansinoids 6. Prior history of solid tumor malignancy within the last 3 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer (patients must have shown no evidence of active disease for 2 years prior to enrollment). 7. Concomitant administration of folate-containing vitamins. 8. Currently receiving anticoagulation with therapeutic doses of warfarin (low-dose warfarin < 2 mg/day is permitted). 9. Patients who have received prior allogeneic or autologous bone marrow transplants 10. WCBP who are pregnant or breast feeding
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online
dana farber logo

450 Brookline Avenue
Boston, MA 02215

Call us toll-free: 866-408-DFCI (3324)

Connect with us

Dana-Farber/Brigham and Women’s Cancer Center is ranked #4 nationally and the best in New England.


Dana-Farber/Boston Children's is ranked the #1 pediatric cancer center.

Sign-up for newsletters